

1 **Alcohol use associated alterations in the circulating metabolite profile in the general**
2 **population and in individuals with major depressive disorder**

3

4 Olli Kärkkäinen^{a,*}, Tommi Tolmunen^{b,c}, Petri Kivimäki^{b,d}, Karoliina Kurkinen^b, Toni Ali-
5 Sisto^b, Pekka Mäntyselkä^{e,f}, Minna Valkonen-Korhonen^{b,g}, Heli Koivumaa-Honkanen^b, Kirsi
6 Honkalampi^h, Anu Ruusunen^{e,g,i}, Vidya Velagapudi^j, Soili M. Lehto^{k,l,m}

7

8 ^a School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland

9 ^b Institute of Clinical Medicine/Psychiatry, University of Eastern Finland, P.O. Box 1627,
10 70211, Kuopio, Finland

11 ^c Department of Adolescent Psychiatry, Kuopio University Hospital, P.O. Box 100. 70029
12 KYS, Finland

13 ^d City of Helsinki, Vuosaari Outpatient Psychiatry Clinic. Postal address: P.O. Box 6250, FI-
14 00099 City of Helsinki, Helsinki, Finland

15 ^e Clinical Research and Trials Centre, Kuopio University Hospital, P.O. Box 100. 70029
16 KYS, Finland

17 ^f Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box
18 1627, 70211, Kuopio, Finland

19 ^g Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland

20 ^h School of Educational Sciences and Psychology, University of Eastern Finland, P.O. Box
21 111, 80101 Joensuu, Finland

22 ⁱ Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical
23 Translation, Food & Mood Centre, IMPACT Strategic Research Centre, School of Medicine,
24 P.O. Box 281, Geelong, VIC 3220, Australia

25 ^j Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, P.O. Box 20, FI-
26 00014 University of Helsinki, Finland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 ^k Institute of Clinical Medicine, University of Oslo, Oslo, Norway

28 ^l R&D Department, Division of Mental Health Services, Akershus University Hospital,
29 Lørenskog, Norway

30 ^m Psychiatry, University of Helsinki and Helsinki University Hospital, P.O. Box 20, FI-00014
31 Helsinki, Finland

32

33 * Correspondence: olli.karkkainen@uef.fi, School of Pharmacy, University of Eastern
34 Finland, P.O. Box 1627, 70211, Kuopio, Finland

35

36 Running title: Alcohol, metabolites, and depression

37

38 Keywords: Depression; Alcoholism; Metabolomics; Hippurate; 5-hydroxyindoleacetic acid

39 ABSTRACT

40 Our aim was to evaluate whether alcohol use is associated with changes in the circulating
41 metabolite profile similar to those present in persons with depression. If so, these findings
42 could partially explain the link between alcohol use and depression. We applied a targeted
43 liquid chromatography mass spectrometry method to evaluate correlates between
44 concentrations of 86 circulating metabolites and self-reported alcohol use in a cohort of the
45 non-depressed general population (GP) (n = 247) and a cohort of individuals with major
46 depressive disorder (MDD) (n = 99). Alcohol use was associated with alterations in
47 circulating concentrations of metabolites in both cohorts. Our main finding was that self-
48 reported alcohol use was negatively correlated with serum concentrations of hippuric acid in
49 the GP cohort. In the GP cohort, consumption of six or more doses per week was associated
50 with low hippuric acid concentrations, similar to those observed in the MDD cohort, but in
51 these individuals it was regardless of their level of alcohol use. Reduced serum
52 concentrations of hippuric acid suggest that already moderate alcohol use is associated with
53 depression-like changes in the serum levels of metabolites associated with gut microbiota and
54 liver function; this may be one possible molecular level link between alcohol use and
55 depression.

56 **Introduction**

57 Heavy alcohol use and lifetime occurrence of alcohol use disorder have been associated with
58 an increased incidence of a major depressive disorder (MDD) (Grant et al., 2015; McHugh &
59 Weiss, 2019; Odlaug et al., 2016). It has been estimated that around one in six of persons
60 with MDD is suffering from a current alcohol use disorder, and that around every third
61 person with MDD has had a lifetime occurrence of alcohol use disorder (DeVido & Weiss,
62 2012; Sullivan et al., 2005; Swendsen et al., 1998). However, the relationship between
63 moderate alcohol use and the incidence of MDD remains controversial: some studies show
64 possible small increase in the incidence of MDD (Odlaug et al., 2016), whereas others have
65 not been able to detect any associations (García-Esquinas et al., 2018) or even found evidence
66 for a reduced incidence of MDD (Bellos et al., 2016). Light alcohol use has not been
67 associated with an increased risk of MDD, and light drinkers are commonly used as controls
68 in these studies (Bellos et al., 2016; García-Esquinas et al., 2018; Grant et al., 2015; Odlaug
69 et al., 2016).

70

71 One possible mediating effect between alcohol use and MDD are changes in the activity of
72 many metabolic processes. Heavy alcohol use has been associated with an altered
73 metabolome (for a review see Voutilainen and Kärkkäinen, 2019). For example, increased
74 levels of glutamate, citrate, alanine, phenylalanine, tyrosine, glucose, docosahexaenoate, 2-
75 piperidone and phosphatidylcholine diacyls, and decreased levels of glutamine, serotonin,
76 asparagine, hydroxysphingomyelins, gamma-aminobutyric acid (GABA) and
77 phosphatidylcholine acyl-alkyls have been associated with heavy alcohol use (Heikkinen et
78 al., 2019; Jaremek et al., 2013; Kärkkäinen, Farokhnia, et al., 2021; Kärkkäinen, Kokla, et al.,
79 2021; Lehtikoinen et al., 2018; Würtz et al., 2016). In a prospective study with an over 30

80 years' follow-up, changes in the circulating metabolome, e.g., decreased levels of serotonin
81 and asparagine, preceded the diagnosis of diseases related to alcohol use (Kärkkäinen et al.,
82 2020). Similarly, also MDD has been associated with alterations in circulating levels of
83 metabolites – some of which have also been linked to alcohol use (e.g., glutamate,
84 phenylalanine, citrate and serotonin; for a review see Gadad et al., 2018). This evidence, in
85 addition to the observed overlap in the incidences of MDD and alcohol use, imply that there
86 may well be some shared underlying pathology related to the disturbances in metabolic
87 processes.

88

89 We have now investigated whether alcohol use would be associated with similar changes in
90 the circulating metabolite profiles irrespective of the presence of depression by measuring the
91 associations between serum metabolite concentrations and self-reported alcohol use in two
92 cohorts: a non-depressed general population (GP) cohort and a cohort of individuals with
93 MDD.

94 **Material and methods**

95 *Study cohorts*

96 Two cohorts were used: 1) a general population cohort of non-depressed individuals (GP
97 cohort), and 2) patients with major depressive disorder (MDD cohort) (Ali-Sisto et al., 2016;
98 Kraav et al., 2019). Both cohorts represented the same population, as Kuopio University
99 Hospital from where the MDD cohort was recruited serves the municipality area of
100 Lapinlahti from where the GP cohort was recruited. The Ethics Committee of Hospital
101 District of Northern Savo approved both studies. Participants provided written informed
102 consent before entering the studies.

103

104 The non-depressed GP cohort was from a population-based follow-up study consisting of 480
105 individuals living in the municipality area of Lapinlahti, Finland in 2005. The sample
106 described here was collected as a part of a 5-year follow-up of the study in 2010 (n = 326) but
107 only participants with alcohol use data (n = 289). Further exclusion criteria were a) Beck
108 Depression Inventory (BDI) score of ≥ 10 at the time of the study or 5 years earlier (Beck,
109 1961), or b) use of medication for depression. After exclusions, a total of 247 subjects were
110 included in the study (Table 1).

111

112 The MDD cohort consisted of 99 outpatients with MDD who were recruited from the
113 Department of Psychiatry of Kuopio University Hospital, Finland. The diagnosis of MDD
114 was confirmed with the structured clinical interview for DSM-IV (SCID) (DSM-IV;
115 American Psychiatric Association, 1994). The exclusion criteria were a) bipolar disorder, b)
116 psychotic disorders, c) a symptomology of mental illness due to alcohol or substance abuse-
117 related diagnosis, d) epilepsy, and e) current somatic conditions preventing participation in

118 the study visits. Most of the participants in the MDD cohort were being administered some
119 form of psychotropic medication: 81 had been prescribed with an antidepressant medication
120 and 48 with an antipsychotic drug with some indication other than a psychotic disease (the
121 medication use has been described in detail in Ali-Sisto, et al. 2016).

122

123 *Alcohol use*

124 The participants in both cohorts completed self-report questionnaires from which the weekly
125 alcohol use was extracted. Response alternatives were: < 1 drink/week, 1-2 drink(s)/week, 3-
126 5 drinks/week, 6-9 drinks/week, 10-14 drinks/week, 15-21 drinks/week, 22-28 drinks/week,
127 or > 28 drinks/week. One standard drink in Finland is defined as a drink containing 12 grams
128 of ethanol. Values higher than 21 drinks per week were considered heavy use, between 6 and
129 21 drinks per week moderate use, and below 6 drinks per week light drinking.

130

131 *Background data, depressive symptoms and psychiatric medications*

132 Background data was collected from the questionnaires completed by the participants.
133 Depressive symptoms were assessed with the Beck Depression Inventory (Beck, 1961) in
134 both cohorts. The use of prescription and over-the-counter medications was also recorded
135 with a questionnaire and confirmed from the prescription documents that the participants
136 provided. The following variables were also collected from both cohorts: age (in years),
137 gender (female/male), regular smoking (yes/no), cohabitation status (married or living with a
138 partner vs. living alone), and education level (higher education yes/no). Use of vegetables and
139 use of fruits (< 1 time/week, 1-5 times/week, > 5 times/week, according to Savolainen et al.
140 2014), and body mass index (BMI) were only available in the GP cohort.

141

142 *Metabolite profiling analysis*

143 Venous blood samples were obtained via venipuncture by trained laboratory personnel and
144 centrifuged to separate the serum. Before venipuncture, the participants were instructed to
145 fast for 12 hours. Serum samples were stored frozen at -80 °C until analyzed. The samples
146 were analyzed in the metabolomics unit of the Institute of Molecular Medicine Finland
147 (FIMM) in Helsinki, Finland. Metabolite profiling analysis of the samples was performed
148 using liquid chromatography-mass spectrometry. Briefly, 10 µL of labeled internal standard
149 mixture was added to the 100 µL of samples, and the samples were allowed to equilibrate
150 with the internal standards. A total of 400 µL of extraction solvent (1% formic acid in
151 acetonitrile) was added and the collected supernatant was dispensed into an Ostro™ 96-well
152 plate (Waters Corporation, Milford, USA) and then filtered by applying a vacuum at a delta
153 pressure of 300–400 mbar for 2.5 minutes on a Hamilton robot's vacuum station. After this, 5
154 µL of filtered sample extract was injected into an Acquity UPLC system coupled to a Xevo®
155 TQ-S triple quadrupole mass spectrometer (Waters Corporation, Milford, MA, USA), which
156 was operated in both positive and negative polarities with a polarity switching time of 20
157 msec for metabolite separation and quantification. The Multiple Reaction Monitoring (MRM)
158 acquisition mode was selected for the quantification of the metabolites. MassLynx 4.1
159 software was used for data acquisition, data handling, and instrument control. The data were
160 processed using TargetLynx software.

161

162 *Statistics*

163 In the comparison of the background characteristics of the cohorts, we used Mann-Whitney U
164 test for continuous and χ^2 test for binomial variables.

165

166 For the metabolite profiling data, only metabolites that were above the quantification limits in
167 at least 50% of subjects in at least one cohort were included in the study. Metabolite
168 concentrations below the quantification limit were excluded from the analysis, with the
169 exception of cotinine, where concentrations below the quantification limit were considered to
170 be zero.

171

172 In the statistical analysis of the metabolite data, the self-reported weekly alcohol drinking
173 levels were coded numerically (1 = < 1 drink/week, 2 = 1–2 drink(s)/week, 3 = 3–5
174 drinks/week, 4 = 6–9 drinks/week, 5 = 10–14 drinks/week, 6 = 15–21 drinks/week, 7 = 22–28
175 drinks/week, and 8 = > 28 drinks/week) to allow us to conduct a regression analysis. We
176 analyzed the two cohorts separately for changes in the metabolite concentrations associated
177 with alcohol use. This was done to focus the analysis on alcohol use related changes, not to
178 changes associated with MDD, which have been reported earlier (Ali-Sisto et al. 2016). We
179 used linear regression to investigate correlations between self-reported weekly alcohol
180 drinking and serum metabolite concentrations. To account for multiple testing, we undertook
181 a principal component analysis and used the number of principal components needed to
182 explain 95% of variance in the datasets to adjust the α -level using Bonferroni's method to
183 0.001 (46 and 41 principal components were needed to explain 95% of variance in the GP
184 and MDD cohorts, respectively). Metabolites with p-values between 0.05 and 0.001 were
185 considered as trends.

186

187 For metabolites with a p-value below 0.05 in the initial analysis, we conducted a post-hoc
188 analysis using linear regression with possible confounders previously associated with alcohol

189 use and/or metabolite levels (age, sex, use of vegetables, use of fruits, smoking, BMI,
190 education level, and cohabitation status) as covariates. We used JASP (version 0.14), SIMCA
191 (version 17, Umetrics), and Prism (GraphPad Software Inc., version 7) for statistical
192 analyses, multivariate analysis, and figure preparation, respectively.

193 **Results**

194 The characteristics of the study participants in both cohorts are presented in Table 1. The GP
195 cohort was older than the MDD cohort. With respect to the selection criteria, as would be
196 expected, the MDD cohort had higher BDI scores when compared to the non-depressed GP
197 cohort. Subjects in the MDD cohort were living alone and smoked regularly more often when
198 compared to the GP cohort.

199

200 The correlations found between self-reported alcohol use and serum metabolite
201 concentrations with p-value below 0.05 in at least one cohort are shown in Figure 1.
202 However, at the multiple testing adjusted α level of 0.001, the only significant correlations
203 were observed between self-reported alcohol use and serum concentrations of hippuric acid
204 and chenodeoxycholic acid in the GP cohort, and xanthosine in the MDD cohort (Figure 1).
205 Correlations with p-values between 0.05 and 0.001 should be considered as trends that need
206 to be validated in larger cohorts. The correlations between self-reported alcohol use and all
207 86 measured metabolites are shown in the Supplementary Table 1.

208

209 A post-hoc analysis was conducted using linear regression with potential confounders. In the
210 GP cohort, most of the correlations between self-reported alcohol use and metabolite levels
211 remained significant after taking into account possible confounders (hippuric acid $\beta = -0.19$,
212 $p = 0.0037$; chenodeoxycholic acid $\beta = 0.19$, $p = 0.0049$; cytidine $\beta = 0.22$, $p = 0.0011$; 5-
213 HIAA $\beta = -0.16$, $p = 0.0183$; taurocholic acid $\beta = 0.22$, $p = 0.0012$; glutamine $\beta = -0.20$, $p =$
214 0.0040 ; and serine $\beta = -0.16$, $p = 0.0218$). There were two exceptions; glycine ($\beta = -0.12$, $p =$
215 0.0785) and cotinine ($\beta = 0.03$, $p = 0.5005$). Instead of alcohol use, sex correlated more with
216 the glycine concentration ($\beta = -0.15$ and $p = 0.0382$) and smoking status more with cotinine

217 concentrations ($\beta = 0.74$, $p < 0.0001$). In the MDD cohort, all metabolites with a p-value
218 below 0.05 in the initial analysis also had a p-value below 0.05 in the linear regression
219 models when lifestyle factors were included as covariates (xanthosine $\beta = -0.38$, $p = 0.0002$;
220 GABA $\beta = 0.25$, $p = 0.0186$; cytidine $\beta = 0.21$, $p = 0.0388$; carnosine $\beta = -0.21$, $p = 0.0348$;
221 and 2-aminoisobutyric acid $\beta = 0.22$, $p = 0.0336$).

222 Discussion

223 Our main finding was that in the GP cohort, at least moderately increased alcohol use was
224 associated with lower serum concentrations of hippuric acid. The hippuric acid
225 concentrations in those individuals who reported six or more alcohol doses per week were
226 similar to the concentrations observed in the MDD cohort regardless of their level of alcohol
227 use (Figure 1). These results are in line with previous reports, where decreased levels of
228 hippuric acid have been associated with alcohol use, depression, anxiety disorders, and stress
229 (J. Chen et al., 2018; Kärkkäinen et al., 2020; Phua et al., 2015; P. Zheng, Wang, et al., 2013;
230 P. Zheng, Chen, et al., 2013). Although rather little is known to explain how hippuric acid
231 might influence behavior, previous studies have found that low hippuric acid levels may
232 impair neuronal development in fetal mouse brain (Ahmed et al., 2022; Vuong et al., 2020).
233 Moreover, in humans, low serum hippuric acid concentrations have been associated with mild
234 cognitive impairment, whereas high levels of hippuric acid have been linked with beneficial
235 effects on cognitive performance (Rutledge et al., 2021; Yilmaz et al., 2020).

236

237 In the GP cohort, similar trends were also seen in the association between self-reported
238 alcohol use and concentrations of 5-HIAA and histidine. Interestingly, the composition of gut
239 microbiota may influence the serum levels of the following three compounds, i.e., hippuric
240 acid (Behr et al., 2017; Fujisaka et al., 2018; Lees et al., 2013; Pessa-Morikawa et al., 2022;
241 Vuong et al., 2020; Williams et al., 2010), 5-HIAA (Lukić et al., 2019), and histidine (H.
242 Chen et al., 2019; Kawase et al., 2017). Moreover, both alcohol use and MDD have been
243 associated with an altered composition and changes in the function of the gut microbiota
244 (Kelly et al., 2016; Leclercq et al., 2014; Llopis et al., 2016; Winter et al., 2018; P. Zheng et

245 al., 2016). Therefore, alterations in the gut microbiota could explain the correlations between
246 serum levels of these metabolites, alcohol use and depression.

247

248 However, in the case of hippuric acid, the gut microbiota first makes benzoic acid from
249 phenolic compounds in the diet, and then the liver forms hippuric acid by combining benzoic
250 acid with glycine (Lees et al., 2013). The declines in serum hippuric acid concentrations
251 could therefore also be a reflection of disturbed liver function since decreased hippuric acid
252 production has been associated with alcohol use and impaired liver function (van Sumere et
253 al., 1969). Furthermore, the intake of vegetables or fruits, the main sources of phenolic
254 compounds in the diet, did not significantly correlate with serum hippuric acid concentrations
255 in the present study. Therefore, differences in the intakes of food items with phenolic
256 compounds are not a likely explanation for the changes we observed in serum levels of
257 hippuric acid. More research is needed to clarify the role of hippuric acid in alcohol use and
258 depression.

259

260 Moreover, we also observed a positive correlation between self-reported alcohol consumption
261 and serum concentrations of two bile acids, chenodeoxycholic acid and taurocholic acid.
262 These correlations could be associated with altered bile acid synthesis or metabolism, which
263 can also be linked with the gut microbiota (Bajaj, 2019). Increases in serum levels of bile
264 acids have been associated with the organ damage induced by alcohol consumption (Bajaj,
265 2019; Milstein et al., 1976; Trinchet et al., 1994). Interestingly, there was no correlation
266 between self-reported alcohol use and chenodeoxycholic acid levels in the MDD cohort,
267 which could be associated with altered cholesterol metabolism in MDD since cholesterol is a
268 starting precursor for bile acid formation (Kraav et al., 2019; Lehto et al., 2010). Moreover,

269 in the MDD cohort, we observed a negative correlation between xanthosine and self-reported
270 alcohol use, which was not observed in the GP cohort. This difference is likely linked to the
271 previously reported dysregulation of purine metabolism in the same cohort (Ali-Sisto et al.,
272 2016).

273

274 Furthermore, there were several metabolites, which were positively (cytidine, taurocholic
275 acid) or negatively (glycine, serine and glutamine) correlated with self-reported alcohol use
276 in both the GP and MDD cohorts with similar standardized β coefficients (Figure 1).

277 However, due to the smaller sample size, these correlations were not statistically significant
278 in the MDD cohort. These alterations are in line with results from previous studies

279 investigating changes associated with alcohol use in the human circulating metabolome

280 (Kärkkäinen et al., 2020; Lehikoinen et al., 2018; Voutilainen & Kärkkäinen, 2019; Würtz et
281 al., 2016).

282

283 Limitations of the study include the relatively small number of subjects in the MDD cohort.

284 Based on the present results, moderate alcohol use seems to be associated with small-to-

285 medium effect size changes in the serum metabolite profile and therefore future studies

286 should examine larger cohorts. We estimated that a sample size of 315 would be needed to

287 observe small-to-medium effect size ($f^2 > 0.1$) correlations between alcohol use and

288 metabolite concentrations with the corrected α level used in the present study (0.0001) with

289 0.95 statistical power. Furthermore, future studies should also use other biomarkers such as

290 phosphatidylethanol, to assess recent alcohol use instead of relying solely on self-reporting

291 (Y. Zheng et al., 2011).

292

293 The present results show that already moderate alcohol use is associated with depression-like
294 changes in the serum levels of a metabolite, hippuric acid, which has been linked with both
295 the gut microbiota and liver function. This indicates that changes in the metabolites
296 associated with the gut microbiota and liver function could be one of the molecular level
297 links between alcohol use and depression, although further research will be needed to verify
298 this hypothesis.

299 **Funding source**

300 This work was supported by The Finnish Foundation for Alcohol Studies (OK), and the
301 Finnish Medical Foundation (SML).

302

303 **Declaration of competing interest**

304 OK is a co-founder of Afekta Technologies Ltd., company providing metabolomics analysis
305 services (not used in the present study). All other authors have no conflicts of interest to
306 declare.

307

308 **Acknowledgements**

309 The authors wish to thank Dr. Jorma Savolainen for his significant contribution in the
310 collection of the Lapinlahti Study sample, and Dr. Ewen MacDonald for proofreading.

311

312 **Data availability statement**

313 The data that support the findings of this study are available on request from the
314 corresponding author, OK. The data are not publicly available due to their containing
315 information that could compromise the privacy of research participants. The study plan
316 approved by the ethical committee and the participant consent terms preclude public sharing
317 of these sensitive data, even in anonymized form.

318 **References**

- 319 Ahmed, H., Leyrolle, Q., Koistinen, V., Kärkkäinen, O., Layé, S., Delzenne, N., & Hanhineva, K. (2022).
320 Microbiota-derived metabolites as drivers of gut-brain communication. *Gut Microbes*, *14*(1),
321 2102878. <https://doi.org/10.1080/19490976.2022.2102878>
- 322 Ali-Sisto, T., Tolmunen, T., Toffol, E., Viinamäki, H., Mäntyselkä, P., Valkonen-Korhonen, M.,
323 Honkalampi, K., Ruusunen, A., Velagapudi, V., & Lehto, S. M. (2016). Purine metabolism is
324 dysregulated in patients with major depressive disorder. *Psychoneuroendocrinology*, *70*, 25–
325 32. <https://doi.org/10.1016/j.psyneuen.2016.04.017>
- 326 Bajaj, J. S. (2019). Alcohol, liver disease and the gut microbiota. *Nature Reviews. Gastroenterology &*
327 *Hepatology*, *16*(4), 235–246. <https://doi.org/10.1038/s41575-018-0099-1>
- 328 Beck, A. T. (1961). An Inventory for Measuring Depression. *Archives of General Psychiatry*, *4*(6), 561.
329 <https://doi.org/10.1001/archpsyc.1961.01710120031004>
- 330 Behr, C., Kamp, H., Fabian, E., Krennrich, G., Mellert, W., Peter, E., Strauss, V., Walk, T., Rietjens, I. M.
331 C. M., & van Ravenzwaay, B. (2017). Gut microbiome-related metabolic changes in plasma of
332 antibiotic-treated rats. *Archives of Toxicology*, *91*(10), 3439–3454.
333 <https://doi.org/10.1007/s00204-017-1949-2>
- 334 Bellos, S., Skapinakis, P., Rai, D., Zitko, P., Araya, R., Lewis, G., Lionis, C., & Mavreas, V. (2016).
335 Longitudinal association between different levels of alcohol consumption and a new onset of
336 depression and generalized anxiety disorder: Results from an international study in primary
337 care. *Psychiatry Research*, *243*, 30–34. <https://doi.org/10.1016/j.psychres.2016.05.049>
- 338 Chen, H., Nwe, P.-K., Yang, Y., Rosen, C. E., Bielecka, A. A., Kuchroo, M., Cline, G. W., Kruse, A. C.,
339 Ring, A. M., Crawford, J. M., & Palm, N. W. (2019). A Forward Chemical Genetic Screen
340 Reveals Gut Microbiota Metabolites That Modulate Host Physiology. *Cell*, *177*(5), 1217-
341 1231.e18. <https://doi.org/10.1016/j.cell.2019.03.036>

- 342 Chen, J., Bai, S.-J., Li, W., Zhou, C., Zheng, P., Fang, L., Wang, H., Liu, Y., & Xie, P. (2018). Urinary
343 biomarker panel for diagnosing patients with depression and anxiety disorders. *Translational*
344 *Psychiatry*, 8(1), 192. <https://doi.org/10.1038/s41398-018-0245-0>
- 345 DeVido, J. J., & Weiss, R. D. (2012). Treatment of the depressed alcoholic patient. *Current Psychiatry*
346 *Reports*, 14(6), 610–618. <https://doi.org/10.1007/s11920-012-0314-7>
- 347 Fujisaka, S., Avila-Pacheco, J., Soto, M., Kostic, A., Dreyfuss, J. M., Pan, H., Ussar, S., Altindis, E., Li, N.,
348 Bry, L., Clish, C. B., & Kahn, C. R. (2018). Diet, Genetics, and the Gut Microbiome Drive
349 Dynamic Changes in Plasma Metabolites. *Cell Reports*, 22(11), 3072–3086.
350 <https://doi.org/10.1016/j.celrep.2018.02.060>
- 351 Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018).
352 Peripheral biomarkers of major depression and antidepressant treatment response: Current
353 knowledge and future outlooks. *Journal of Affective Disorders*, 233, 3–14.
354 <https://doi.org/10.1016/j.jad.2017.07.001>
- 355 García-Esquinas, E., Ortola, R., Galán, I., Soler-Vila, H., Laclaustra, M., & Rodríguez-Artalejo, F. (2018).
356 Moderate alcohol drinking is not associated with risk of depression in older adults. *Scientific*
357 *Reports*, 8(1), 11512. <https://doi.org/10.1038/s41598-018-29985-4>
- 358 Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J.,
359 Smith, S. M., Huang, B., & Hasin, D. S. (2015). Epidemiology of DSM-5 Alcohol Use Disorder:
360 Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. *JAMA*
361 *Psychiatry*, 72(8), 757. <https://doi.org/10.1001/jamapsychiatry.2015.0584>
- 362 Heikkinen, N., Kärkkäinen, O., Laukkanen, E., Kekkonen, V., Kaarre, O., Kivimäki, P., Könönen, M.,
363 Velagapudi, V., Nandania, J., Lehto, S. M., Niskanen, E., Vanninen, R., & Tolmunen, T. (2019).
364 Changes in the serum metabolite profile correlate with decreased brain gray matter volume
365 in moderate-to-heavy drinking young adults. *Alcohol*, 75, 89–97.
366 <https://doi.org/10.1016/j.alcohol.2018.05.010>

- 367 Jaremek, M., Yu, Z., Mangino, M., Mittelstrass, K., Prehn, C., Singmann, P., Xu, T., Dahmen, N.,
368 Weinberger, K. M., Suhre, K., Peters, A., Döring, A., Hauner, H., Adamski, J., Illig, T., Spector,
369 T. D., & Wang-Sattler, R. (2013). Alcohol-induced metabolomic differences in humans.
370 *Translational Psychiatry*, 3(7), e276–e276. <https://doi.org/10.1038/tp.2013.55>
- 371 Kärkkäinen, O., Farokhnia, M., Klåvus, A., Auriola, S., Lehtonen, M., Deschaine, S. L., Piacentino, D.,
372 Abshire, K. M., Jackson, S. N., & Leggio, L. (2021). Effect of intravenous ghrelin
373 administration, combined with alcohol, on circulating metabolome in heavy drinking
374 individuals with alcohol use disorder. *Alcoholism, Clinical and Experimental Research*, 45(11),
375 Article 11. <https://doi.org/10.1111/acer.14719>
- 376 Kärkkäinen, O., Klåvus, A., Voutilainen, A., Virtanen, J., Lehtonen, M., Auriola, S., Kauhanen, J., &
377 Rysä, J. (2020). Changes in circulating metabolome precede alcohol-related diseases in
378 middle-aged men: A prospective population-based study with a 30-year follow-up.
379 *Alcoholism: Clinical and Experimental Research*, 44, 2457–2467.
380 <https://doi.org/10.1111/acer.14485>
- 381 Kärkkäinen, O., Kokla, M., Lehtonen, M., Auriola, S., Martiskainen, M., Tiihonen, J., Karhunen, P. J.,
382 Hanhineva, K., & Kok, E. (2021). Changes in the metabolic profile of human male
383 postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol
384 use. *Addiction Biology*, e13035. <https://doi.org/10.1111/adb.13035>
- 385 Kawase, T., Nagasawa, M., Ikeda, H., Yasuo, S., Koga, Y., & Furuse, M. (2017). Gut microbiota of mice
386 putatively modifies amino acid metabolism in the host brain. *British Journal of Nutrition*,
387 117(6), 775–783. <https://doi.org/10.1017/S0007114517000678>
- 388 Kelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott,
389 K., Moloney, G., Hoban, A. E., Scott, L., Fitzgerald, P., Ross, P., Stanton, C., Clarke, G., Cryan,
390 J. F., & Dinan, T. G. (2016). Transferring the blues: Depression-associated gut microbiota
391 induces neurobehavioural changes in the rat. *Journal of Psychiatric Research*, 82, 109–118.
392 <https://doi.org/10.1016/j.jpsychires.2016.07.019>

- 393 Kraav, S.-L., Tolmunen, T., Kärkkäinen, O., Ruusunen, A., Viinamäki, H., Mäntyselkä, P., Koivumaa-
394 Honkanen, H., Valkonen-Korhonen, M., Honkalampi, K., Herzig, K.-H., & Lehto, S. M. (2019).
395 Decreased serum total cholesterol is associated with a history of childhood physical violence
396 in depressed outpatients. *Psychiatry Research*, *272*, 326–333.
397 <https://doi.org/10.1016/j.psychres.2018.12.108>
- 398 Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli,
399 V., Bäckhed, F., Verbeke, K., de Timary, P., & Delzenne, N. M. (2014). Intestinal permeability,
400 gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. *Proceedings*
401 *of the National Academy of Sciences*, *111*(42), E4485–E4493.
402 <https://doi.org/10.1073/pnas.1415174111>
- 403 Lees, H. J., Swann, J. R., Wilson, I. D., Nicholson, J. K., & Holmes, E. (2013). Hippurate: The Natural
404 History of a Mammalian–Microbial Cometabolite. *Journal of Proteome Research*, *12*(4),
405 1527–1546. <https://doi.org/10.1021/pr300900b>
- 406 Lehtikoinen, A. I., Kärkkäinen, O. K., Lehtonen, M. A. S., Auriola, S. O. K., Hanhineva, K. J., & Heinonen,
407 S. T. (2018). Alcohol and substance use are associated with altered metabolome in the first
408 trimester serum samples of pregnant mothers. *European Journal of Obstetrics & Gynecology*
409 *and Reproductive Biology*, *223*, 79–84. <https://doi.org/10.1016/j.ejogrb.2018.02.004>
- 410 Lehto, S. M., Niskanen, L., Tolmunen, T., Hintikka, J., Viinamäki, H., Heiskanen, T., Honkalampi, K.,
411 Kokkonen, M., & Koivumaa-Honkanen, H. (2010). Low serum HDL-cholesterol levels are
412 associated with long symptom duration in patients with major depressive disorder: HDL-C
413 and the duration of depression. *Psychiatry and Clinical Neurosciences*, *64*(3), 279–283.
414 <https://doi.org/10.1111/j.1440-1819.2010.02079.x>
- 415 Llopis, M., Cassard, A. M., Wrzosek, L., Boschat, L., Bruneau, A., Ferrere, G., Puchois, V., Martin, J. C.,
416 Lepage, P., Le Roy, T., Lefèvre, L., Langelier, B., Cailleux, F., González-Castro, A. M., Rabot, S.,
417 Gaudin, F., Agostini, H., Prévot, S., Berrebi, D., ... Perlemuter, G. (2016). Intestinal microbiota

- 418 contributes to individual susceptibility to alcoholic liver disease. *Gut*, 65(5), 830–839.
- 419 <https://doi.org/10.1136/gutjnl-2015-310585>
- 420 Lukić, I., Getselter, D., Koren, O., & Elliott, E. (2019). Role of Tryptophan in Microbiota-Induced
421 Depressive-Like Behavior: Evidence From Tryptophan Depletion Study. *Frontiers in*
422 *Behavioral Neuroscience*, 13, 123. <https://doi.org/10.3389/fnbeh.2019.00123>
- 423 McHugh, R. K., & Weiss, R. D. (2019). Alcohol Use Disorder and Depressive Disorders. *Alcohol*
424 *Research : Current Reviews*, 40(1), arcr.v40.1.01. <https://doi.org/10.35946/arcr.v40.1.01>
- 425 Milstein, H. J., Bloomer, J. R., & Klatskin, G. (1976). Serum bile acids in alcoholic liver disease.
426 Comparison with histological features of the disease. *The American Journal of Digestive*
427 *Diseases*, 21(4), 281–285. <https://doi.org/10.1007/BF01071839>
- 428 Odlaug, B. L., Gual, A., DeCourcy, J., Perry, R., Pike, J., Heron, L., & Rehm, J. (2016). Alcohol
429 Dependence, Co-occurring Conditions and Attributable Burden. *Alcohol and Alcoholism*,
430 51(2), 201–209. <https://doi.org/10.1093/alcalc/agv088>
- 431 Pessa-Morikawa, T., Husso, A., Kärkkäinen, O., Koistinen, V., Hanhineva, K., Iivanainen, A., & Niku, M.
432 (2022). Maternal microbiota-derived metabolic profile in fetal murine intestine, brain and
433 placenta. *BMC Microbiology*, 22(1), 46. <https://doi.org/10.1186/s12866-022-02457-6>
- 434 Phua, L. C., Wilder-Smith, C. H., Tan, Y. M., Gopalakrishnan, T., Wong, R. K., Li, X., Kan, M. E., Lu, J.,
435 Keshavarzian, A., & Chan, E. C. Y. (2015). Gastrointestinal Symptoms and Altered Intestinal
436 Permeability Induced by Combat Training Are Associated with Distinct Metabotypic Changes.
437 *Journal of Proteome Research*, 14(11), 4734–4742.
438 <https://doi.org/10.1021/acs.jproteome.5b00603>
- 439 Rutledge, G. A., Sandhu, A. K., Miller, M. G., Edirisinghe, I., Burton-Freeman, B. B., & Shukitt-Hale, B.
440 (2021). Blueberry phenolics are associated with cognitive enhancement in supplemented
441 healthy older adults. *Food & Function*, 12(1), 107–118. <https://doi.org/10.1039/d0fo02125c>

- 442 Sullivan, L. E., Fiellin, D. A., & O'Connor, P. G. (2005). The prevalence and impact of alcohol problems
443 in major depression: A systematic review. *The American Journal of Medicine*, *118*(4), 330–
444 341. <https://doi.org/10.1016/j.amjmed.2005.01.007>
- 445 Swendsen, J. D., Merikangas, K. R., Canino, G. J., Kessler, R. C., Rubio-Stipec, M., & Angst, J. (1998).
446 The comorbidity of alcoholism with anxiety and depressive disorders in four geographic
447 communities. *Comprehensive Psychiatry*, *39*(4), 176–184. [https://doi.org/10.1016/s0010-](https://doi.org/10.1016/s0010-440x(98)90058-x)
448 [440x\(98\)90058-x](https://doi.org/10.1016/s0010-440x(98)90058-x)
- 449 Trinchet, J. C., Gerhardt, M. F., Balkau, B., Munz, C., & Poupon, R. E. (1994). Serum bile acids and
450 cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features.
451 *Journal of Hepatology*, *21*(2), 235–240. [https://doi.org/10.1016/s0168-8278\(05\)80401-5](https://doi.org/10.1016/s0168-8278(05)80401-5)
- 452 van Sumere, C. F., Teuchy, H., Pé, H., Verbeke, R., & Bekaert, J. (1969). Quantitative investigation on
453 the hippuric acid formation in healthy and diseased individuals. *Clinica Chimica Acta*, *26*(1),
454 85–88. [https://doi.org/10.1016/0009-8981\(69\)90289-7](https://doi.org/10.1016/0009-8981(69)90289-7)
- 455 Voutilainen, T., & Kärkkäinen, O. (2019). Changes in the Human Metabolome Associated With
456 Alcohol Use: A Review. *Alcohol and Alcoholism*, *54*(3), 225–234.
457 <https://doi.org/10.1093/alcalc/agz030>
- 458 Vuong, H. E., Pronovost, G. N., Williams, D. W., Coley, E. J. L., Siegler, E. L., Qiu, A., Kazantsev, M.,
459 Wilson, C. J., Rendon, T., & Hsiao, E. Y. (2020). The maternal microbiome modulates fetal
460 neurodevelopment in mice. *Nature*, *586*(7828), 281–286. [https://doi.org/10.1038/s41586-](https://doi.org/10.1038/s41586-020-2745-3)
461 [020-2745-3](https://doi.org/10.1038/s41586-020-2745-3)
- 462 Williams, H. R., Cox, I. J., Walker, D. G., Cobbold, J. F., Taylor-Robinson, S. D., Marshall, S. E., &
463 Orchard, T. R. (2010). Differences in gut microbial metabolism are responsible for reduced
464 hippurate synthesis in Crohn's disease. *BMC Gastroenterology*, *10*(1), 108.
465 <https://doi.org/10.1186/1471-230X-10-108>

- 466 Winter, G., Hart, R. A., Charlesworth, R. P. G., & Sharpley, C. F. (2018). Gut microbiome and
467 depression: What we know and what we need to know. *Reviews in the Neurosciences*, 29(6),
468 629–643. <https://doi.org/10.1515/revneuro-2017-0072>
- 469 Würtz, P., Cook, S., Wang, Q., Tiainen, M., Tynkkynen, T., Kangas, A. J., Soininen, P., Laitinen, J.,
470 Viikari, J., Kähönen, M., Lehtimäki, T., Perola, M., Blankenberg, S., Zeller, T., Männistö, S.,
471 Salomaa, V., Järvelin, M.-R., Raitakari, O. T., Ala-Korpela, M., & Leon, D. A. (2016). Metabolic
472 profiling of alcohol consumption in 9778 young adults. *International Journal of*
473 *Epidemiology*, 45(5), 1493–1506. <https://doi.org/10.1093/ije/dyw175>
- 474 Yilmaz, A., Ugur, Z., Bisgin, H., Akyol, S., Bahado-Singh, R., Wilson, G., Imam, K., Maddens, M. E., &
475 Graham, S. F. (2020). Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker
476 Panel for the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment: A Pilot Study.
477 *Metabolites*, 10(9), E357. <https://doi.org/10.3390/metabo10090357>
- 478 Zheng, P., Chen, J., Huang, T., Wang, M., Wang, Y., Dong, M., Huang, Y., Zhou, L., & Xie, P. (2013). A
479 Novel Urinary Metabolite Signature for Diagnosing Major Depressive Disorder. *Journal of*
480 *Proteome Research*, 12(12), 5904–5911. <https://doi.org/10.1021/pr400939q>
- 481 Zheng, P., Wang, Y., Chen, L., Yang, D., Meng, H., Zhou, D., Zhong, J., Lei, Y., Melgiri, N. D., & Xie, P.
482 (2013). Identification and validation of urinary metabolite biomarkers for major depressive
483 disorder. *Molecular & Cellular Proteomics: MCP*, 12(1), 207–214.
484 <https://doi.org/10.1074/mcp.M112.021816>
- 485 Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J., Fan, S., Du, X., Zhang, X., Yang,
486 D., Yang, Y., Meng, H., Li, W., Melgiri, N. D., Licinio, J., Wei, H., & Xie, P. (2016). Gut
487 microbiome remodeling induces depressive-like behaviors through a pathway mediated by
488 the host’s metabolism. *Molecular Psychiatry*, 21(6), 786–796.
489 <https://doi.org/10.1038/mp.2016.44>
- 490 Zheng, Y., Beck, O., & Helander, A. (2011). Method development for routine liquid chromatography–
491 mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in

492 blood. *Clinica Chimica Acta*, 412(15–16), 1428–1435.

493 <https://doi.org/10.1016/j.cca.2011.04.022>


494

495 Table 1: Background characteristics of the study cohorts.

Variable	Cohort		test value	p-value
	GP (n = 247)	MDD (n=99)		
Age (years, mean \pm SD)	54.6 (\pm 9.5)	39.4 (\pm 11.9)	4213 ^b	<0.0001
Gender (% females)	118 (48 %)	56 (56%)	2 ^a	0.1393
Living with a partner (n, %)	206 (83%)	52 (53%)	37 ^a	<0.0001
BDI score (mean \pm SD)	3 (\pm 2)	28 (\pm 12)	22733 ^b	<0.0001
Self-reported alcohol use (n, %)			13 ^a	0.0742
Light alcohol use	192 (78%)	77 (78%)		
< 1 doses/week	75 (30%)	34 (34%)		
1-2 doses/week	59 (24%)	26 (26%)		
3-5 doses/week	58 (23%)	17 (17%)		
Moderate alcohol use	54 (22%)	19 (19%)		
6-9 doses/week	26 (10%)	15 (15%)		
10-14 doses/week	23 (9%)	2 (2%)		
15-21 doses/week	5 (2%)	2 (2%)		
Heavy alcohol use	1 (0.4%)	3 (3%)		
22-28 doses/week	1 (0.4%)	2 (2%)		
>28 doses/week	0 (0%)	1 (2%)		
Smoking (n, %)	48 (19%)	33 (33%)	18 ^a	<0.0001
Antidepressant use (n, %)	0 (0%)	84 (85%)	277 ^a	<0.0001
BMI (mean \pm SD)	28 (\pm 5)	-		
Use of vegetables (n, %)				
>5 times/week	81 (32%)	-		
1-5 times/week	85 (34%)	-		
<1 times/week	86 (34%)	-		
Use of fruits (n, %)				
>5 times/week	95 (38%)	-		
1-5 times/week	88 (35%)	-		
<1 times/week	69 (27%)	-		

496

497 Legend: GP, general population cohort; MDD, cohort of patients with a major depressive
 498 disorder; BDI, Beck Depression Inventory; BMI, body mass index; SD, standard deviation;
 499 significant difference between the study cohorts as evaluated by: ^a = χ^2 test, or ^b = Mann-
 500 Whitney U test.



501

502 **Figure 1: Metabolites associated with self-reported alcohol use.** Standardized β
 503 coefficients are shown (with 95% confidence intervals as dashed lines) for linear regression
 504 models between measured metabolites and self-reported alcohol use with negative (A) or
 505 positive (B) correlations. After correction for multiple testing, only correlations between self-
 506 reported alcohol use and chenodeoxycholic acid, hippuric acid and xanthosine can be viewed
 507 as significant (p-values below multiple testing adjusted α of 0.001). Other correlations should
 508 be considered as trends. Legend: GP, general population cohort; MDD, major depressive
 509 disorder cohort; β , standardized β coefficient from linear regression model; p, p-value from
 510 linear regression model; *, p-value < 0.001 (Bonferroni adjusted α level).